Medical Ventures Corp.

Medical Ventures Corp.

April 10, 2006 17:12 ET

Medical Ventures Corp.: Metricath Gemini GAAME Clinical Trial Update

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - April 10, 2006) - MEDICAL VENTURES CORP. (TSX VENTURE:MEV), a medical technology company specializing in cardiovascular devices, announces two additional research sites have begun enrolling patients in the clinical trial evaluating its Metricath® Gemini product.

Called "GAAME" - for Gemini Angioplasty and Arterial Measurement Evaluation - the trial assesses the safety and effectiveness of using the Metricath Gemini catheter system to treat diseased coronary arteries. The data from the trial will support the company's application for approval from the U.S. Food and Drug Administration (FDA) to use the Gemini in coronary arteries. There are over one million cardiac catheterizations performed in the U.S. each year, representing a significant market opportunity.

Patient enrolment is underway after completion of required regulatory processes. In addition to Mercy Heart Institute in Sacramento, CA, patients are now actively enrolling at the University of Oklahoma Health Sciences Center and at the study's principal investigation site, the Thoraxcenter Erasmus MC in Rotterdam, Netherlands. The Thoraxcenter is considered among the world's most respected facilities for scientific research and education in the field of cardiology and cardiothoracic surgery. A fourth site, the Florida Cardiovascular Institute in Tampa, is expected to begin enrolling patients shortly.

The GAAME study's total number of research sites is also expanding, as the FDA recently granted approval for three new sites to take part. These additions will bring the total number of allowable sites in the U.S. to nine, from an initial pool of six. Adding to the number of sites increases the potential for patient enrolment and faster completion of the trial. Research centres not yet actively enrolling patients are undergoing regulatory procedures that include an ethics review and physician training.

"We are very pleased to have the additional centres join the GAAME study, and we look forward to increasing patient enrolment," says Medical Ventures' president and CEO, Paul Geyer. "The more sites and patients we have participating, the more quickly we can expect to bring this innovative and easy-to-use technology to market."

Metricath Gemini's catheter-based technology assists physicians in diagnosing and treating patients who suffer from cardiovascular diseases. The Metricath System accurately measures the size and area of patients' arteries and of "stents", metallic, mesh tubes implanted into vessels to improve and maintain proper blood flow. The measurements help physicians to select appropriate stents for implantation and to ensure they are placed properly within arteries.

The Gemini is unique in that it gives physicians the ability to measure and treat blocked arteries with a single catheter. Because current practice requires two separate catheters, one to measure and another for treatment, the Gemini offers users savings in both time and cost. At present, the Gemini has FDA clearance for use in peripheral (non-coronary) arteries, such as those in the kidney and thigh.

Medical Ventures Corp. (TSX VENTURE:MEV) is a medical device company dedicated to acquiring and developing medical technologies. The company addresses clinical needs in the cardiovascular and surgical marketplace to provide innovative solutions for patient care.

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates", "believes", "may", "continue", "estimates", "expects", and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information